Kelvin Moses MD, PhD

Associate Professor
Department of Urology
Fellowship Director
Urologic Oncology Fellowship
Division of Urologic Oncology

Medical School: Baylor College of Medicine, Houston, TX
Residency: Emory University School of Medicine, Atlanta, GA
Fellowship: Memorial Sloan-Kettering Cancer Center, New York, NY
Clinical Interests: Advanced Prostate Cancer, Advanced Kidney Cancer, Testis Cancer, Penile Cancer, Adrenal Cancer

Dr. Moses is the Director of the Comprehensive Prostate Cancer clinic and has research interests in health literacy and cancer outcomes, advanced prostate cancer clinical trials, and health disparities in Urologic cancers.

Active Clinical Trials

Talapro-2 (Pfizer)

Newly diagnosed mCRPC (no prior systemic therapy in this state) to receive enza +/- talazoparib, primary outcome rPFS, secondary outcome OS)

Learn more about this trial

PI: Kelvin Moses, MD

Janssen

Neo-adjuvant and adjuvant apalutamide/placebo plus ADT in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy

Learn more about this study

PI: Kelvin Moses, MD

CPI-1205 ProSTAR

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

Learn more about this study

PI: Kelvin Moses, MD

Dendreon Active Surveillance

A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate cancer, Protocol P17-1

Learn more about this trial

PI: Kelvin Moses, MD